NCT07874529Active, not recruiting
Cervical Cytology DNA Methylation for Endometrial Cancer Screening
A Real-world Study on the Use of Cervical Cytology Methylation Testing for the Screening of Endometrial Cancer
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This study intends to conduct the "Real-world Study on Cervical Cytology Methylation Testing for Endometrial Cancer Screening" project through a multi-center real-world research approach. Led by Peking Union Medical College Hospital, at least 10 institutions will participate in the study. The goal is to complete the enrollment of at least 30 million real-world samples. Focusing on the changes in DNA methylation levels in cervical exfoliated cells as the research entry point, this study aims to provide new ideas and theoretical basis for preventing and treating endometrial cancer by targeting the CDO1/CELF4 double gene methylation. The expectation is to achieve the clinical application of a more optimal endometrial cancer screening protocol, improve the current shortcomings of endometrial cancer screening, make endometrial cancer screening more accurate, effectively reduce the incidence of endometrial cancer, and avoid excessive medical treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 30000 (estimated)
- First submitted
- 8 Oct 2026
- Start date
- 12 Dec 2025
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Lei Li
- Diseases
- Endometrial cancer
- NCT number
- NCT07874529
What you commit to
- Study type: Observational
- Planned participants: 30000
- From 12 Dec 2025 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cancer of the female reproductive system under treatment (except for endometrial cancer);
- Active bleeding from the lower genital tract;
- Immunosuppressed state (such as after HIV infection, organ transplantation, etc.)
Other
- Did not meet all the inclusion criteria.
- Others (including those that the researchers deemed unsuitable for inclusion).
Who the study is looking for
- Age is 18 years old or above.
- Agree to undergo the routine methylation test for endometrial cancer and participate in the study;
- The medical records are complete and include the results of endometrial tissue pathology examination.
- Be informed of the relevant risks of the project and voluntarily sign the informed consent form.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.